Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25647564 | 0.90 | NNMT (0.51) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL10222121 | 0.90 | NNMT (0.51) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL6112690 | 0.86 | ALDH1A1 (0.49) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL13178928 | 0.85 | NNMT (0.47) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL13254935 | 0.85 | NNMT (0.47) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL25842908 | 0.85 | LCK (0.49) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL28285146 | 0.83 | CYP3A4 (0.61) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL26552884 | 0.82 | HPGD (0.47) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL26551435 | 0.82 | POLB (0.56) | NNMTKDM4EALDH1A1GLAGAA | |
| SCHEMBL2424366 | 0.81 | ALDH1A1 (0.50) | NNMTKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | claimed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | claimed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2459541-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| EP-2393781-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| EP-2099765-A2 | 5, 6, OR 7-SUBSTITUTED-3-(HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | Rexahn Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008063548-A2 | 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | REXAHN PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | NNMT 899/4885KDM4E 2644/4885ALDH1A1 1399/4885 |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | P2RX3, P2RX1, P2RY1 | NNMT 1496/4885KDM4E 2570/4885ALDH1A1 1147/4885 |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | NNMT 1340/4885KDM4E 2728/4885ALDH1A1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.